Axsm

[merlin8121]

Altro titolo molto interessante per il Biorunp nel breve è Axsome, con diversi catalyst in arrivo ed a sconto in questo momento. Con cash fino al 2020.
Ultimo target ricevuto 16us il 15 no da Cantor.

Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update



CCI pronto ad incrociare segnale buy.

 

[roscfh]

catalist quando?

 

[merlin8121]

catalist quando?

C'è tutto nelle prime righe del link.

 

[roscfh]

Fase 2 di AXS 05 è previsto entro fine anno. Non vorrei uscisse a sorpresa e si prende la mazzata

 

[merlin8121]

Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019

Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018

Phase 2/3 interim analysis results of AXS-05 in Alzheimer’s disease agitation anticipated in 4Q 2018

Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4Q 2018 to 1Q 2019

Phase 2 trial of AXS-12 in narcolepsy anticipated to start in 4Q 2018

Ne ha diversi in arrivo da qui a gennaio.

 

[roscfh]

Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018

Phase 2/3 interim analysis results of AXS-05 in Alzheimer’s disease agitation anticipated in 4Q 2018

Ne ha diversi in arrivo da qui a gennaio.

Appunto, ma se questi due vanno male sono scoppole..

 

[merlin8121]

Volumi bassi tuttavia una bella salita ieri (7,43%) , in una giornata rosso sangue.
CCI ormai all'incrocio. Dovrebbe continuare.

 

[merlin8121]

Continua ad essere interessante in vista dei prossimi catalyst.

 

[merlin8121]

Si riavvicina al punto di break.

 

[merlin8121]

Primo catalyst è andato bene, vediam che fà oggi-
IDMC recommends continuation of trial evaluating AXS-05 versus placebo in Alzheimer’s disease agitation

IDMC recommends no further enrollment to single-agent bupropion arm

NEW YORK, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a positive outcome of the interim analysis for the ADVANCE-1 Phase 2/3 trial of AXS-05 in agitation associated with Alzheimer’s disease (AD). An independent data monitoring committee (IDMC) conducted the unblinded, pre-specified interim analysis for futility. Based on the results of the analysis, the IDMC recommended continuation of the AXS-05 treatment arm. Additionally, the IDMC recommended no further randomization of subjects to the bupropion treatment arm of the study. The IDMC did not indicate that there were any safety concerns in the study. Axsome intends to follow the IDMC’s recommendations.

 

[papi67]

Primo catalyst è andato bene, vediam che fà oggi-
IDMC recommends continuation of trial evaluating AXS-05 versus placebo in Alzheimer’s disease agitation

IDMC recommends no further enrollment to single-agent bupropion arm

NEW YORK, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a positive outcome of the interim analysis for the ADVANCE-1 Phase 2/3 trial of AXS-05 in agitation associated with Alzheimer’s disease (AD). An independent data monitoring committee (IDMC) conducted the unblinded, pre-specified interim analysis for futility. Based on the results of the analysis, the IDMC recommended continuation of the AXS-05 treatment arm. Additionally, the IDMC recommended no further randomization of subjects to the bupropion treatment arm of the study. The IDMC did not indicate that there were any safety concerns in the study. Axsome intends to follow the IDMC’s recommendations.

se regge un paio di giorni.............

 

[merlin8121]

Hanno pure annunciato il fail del secondo trial , 1 ora dopo.

 

[papi67]

Hanno pure annunciato il fail del secondo trial , 1 ora dopo.

........ccccci loro.